SANA Sana Biotechnology Inc

$SANA so, the only news out of today’s conference call is that the first diabetes patient may be dosed in the new year because of the holidays at the end of 2026. Steve expects the IND to clear this year, still.

$SANA thesis change: promising fusogen technology+ another 1-2 quarters of execution and financing risk before human validation.

$SANA crap news today. Fusogen trial pushed back upwards of 6 months. First data now 1H 2027 while Multiple Myeloma trial now 2027 rather than mid-2027. Finally, for SC451, neither tech transfer to CDMO nor preclinical studies have been completed so no filing yet with FDA.

Companies have 4 business days to file a form 8-K from the date of the material event so if Mayo opts in I would think an SEC filing by $SANA would be from today thru Friday.

$SANA is a classic high-risk, high-reward biotech setup. The upside rests mainly on SC451 for Type 1 diabetes and SG293 for B-cell cancers/autoimmune disease. SC451 is backed by encouraging HIP-platform data, while SG293 could validate Sana’s in-vivo CAR-T approach. The problem is funding. Cash is only ~$57M, H1 R&D was ~$59M, and management has warned current resources won’t cover planned operations for the next 12 months. Dilution is already happening: shares outstanding rose ~12% in H1, and SANA still has ATM capacity left. My view: around $3 can be interesting for a small speculative position, with room to add near $2. If clinical news drives a big spike, I’d consider taking partial profits because more equity issuance remains a real risk.

$SANA I missed most of the call and just relied on the transcripts, but it was quite garbbled. The impression I had is everything is still on track for SC451 with dosing before the end of 2026. Two of three milestones are pretty much done and the third is the tech transfer to Fuji, which continues. On the FDA comments, didn't see anything that would cause concern there. In fact, my impression is if you don't get the package / application with all the data in correctly the first time, you only get one chance to make a go at the application. Subsequent amendments and updates, raise red flags and are slower in processing than had it been done all correctly the first time - with everything dotted and crossed. So yes, I'm impatient but understand it's better to get it all through compliance the first and only time before getting the green light on dosing. As Brian mentioned to me, what's waiting a few more weeks or months, in lieu if having T1D forever. On track from what I could read.

$SANA SC451 Trial was expected to begin in 2026. It’s September with no sign of it happening anytime soon. I’m getting impatient.

$SANA Bought 400 shares at $3.82 this morning. Hanging in until the Investor Calls next week. Good luck to everyone!

$SANA here's the charge against Harr: enormous resources consumed, repeated strategic resets, and still too little clinical validation for the amount of capital committed...Harr's decisions about scope, spending and prioritization are going to look considerably harder to defend if this keeps up.

$SANA “in China” = tech/ip stolen & likely being worked on by gov’t backed bio. Will change one letter in patent app to not give u a penny. Broke US bio can sue China or invade. Good luck. Look at the o/s!! 300m shares (200m+ since upsala)+ 2yrs & they haven’t finished paperwork or prep, well enough even started 1 of 2 trials. Smh. 🤦‍♂️. What have they been doing? Porn? Abandon everything but t1d, quit the f’ing tours, fire all r&d/non essentials, cut every expense & do ur f’ing homework. Looking @ 700m o/s at best before a p3. That rerate to $6 is assuming finished & success. From $40+ pps min just in T1d to $6. Gtfoh. Going back to $2 before bankruptcy or fire sale.

$SANA On the other comments of the in-vivo technology, this is the first time I'm hearing they are doing work in China. Never have I read or heard about that in any filings or discussions. There wasn't much said about the delay or what kind of hiccup has occured. I'm also not entirely surprised to learn they're doing biotech work in China. The whole biotech sector has been growing extremly qucikly but surprising they're in China. Best thing they can do with that program is get a Chinese biotech to venture with them / fund the work / carve out that section of the business. It's extremely competitive and the future cash burn is massive. Hopefully they've a grant with a government body doing the IST or a university if footing some of the bill.

$SANA IF Mayo elected they have 10-20 days to close. Sec "3.2 Second Closing" in https://www.sec.gov/Archives/edgar/data/1770121/000119312526152868/sana-ex10_1.htm But also fear this could've been fair warning from the Aug 10q:"As of the filing of this Quarterly Report, Mayo Clinic has not elected to purchase the Additional Shares." While it isn't the end of the world, or sc451, if Mayo didn't agree to the 2nd tranche, it is in my _opinion_ a very red flag, and if I had to guess it's something around ph 1/2 scheduling. Time will tell what's happening or what happened with Mayo and the second tranche. Anyone else feeling a little disappointed here too as of right now?

$SANA to summarize Malone's screenshots, etc.: Sana Bio. is a high risk, high upside biotech whose low current expectations could be transformed by successful clinical validation of its immune-evasive diabetes and in-vivo CAR-T technologies? am I close? without access to the PDF, that's all I can come up with.

$SANA I will take $6 B of A Securities analyst Alex Stranahan maintains Sana Biotechnology (NASDAQ:SANA) with a Buy and lowers the price target from $7 to $6

$SANA I am not feeling very bullish with no Mayo news but the chart is feeling very bullish. Such a pretty setup. Have a Cup and Handle (again) potentially leading to a breakout. Need to push above critical resistance (red line) 4.09, and hopefully just blast through. <=3.52 is the stop. No trades open for me right now in Sana, but considering it. Obviously have my investment position ive been acquiring over the past however many years its been now, that doesn't get any shares sold until I get sc451, or God forbid some unforeseen craziness in trials.

$SANA so did every pharmaceutical crash in unison just because that Lp(a) reduction drug didn’t produce meaningful cardiovascular results?

$SANA It has also announced a collaboration with Mayo Clinic to advance SC451 development, in connection with which Mayo made an equity investment of approximately US$25.0 million with an option for approximately US$25.0 million more. The caveat is scale. The UP421 results are from a very small number of patients in an investigator-sponsored setting, and gene editing adds manufacturing and regulatory complexity that a physical barrier does not. But it is the most direct assault on the immunosuppression problem anyone has landed in a human so far.

$SANA Approach Two: Hide the Cells Sana Biotechnology, Inc. (Nasdaq: SANA) has taken the genetic route. Its hypoimmune platform edits cells so that the immune system does not recognize them as foreign in the first place, removing the need for immunosuppressive drugs rather than managing them. The company reported 12-month clinical results from an investigator-sponsored study of UP421, an allogeneic primary islet cell therapy engineered with that technology and transplanted into a patient with Type 1 diabetes without any immunosuppression. The cells were reported as safe and well tolerated, evading immune detection and continuing to function a year after transplant. Twelve-week results from the same study were published in the New England Journal of Medicine . Sana is now applying the tested technology to SC451, a hypoimmune-modified, stem cell-derived therapy intended as a one-time treatment with the stated goal of normal blood glucose with no insulin and no immunosuppression.